Core Insights - The 17th China Bioindustry Conference showcased cutting-edge technologies in the biological field, emphasizing the theme "Biotechnology Empowers the Future, Biomanufacturing Reshapes the World" [1] - The conference serves as a significant booster for the development of China's bioindustry, facilitating deep integration of industry, academia, and research to accelerate technology transfer and resource integration [1] Company Highlights - Shanghai United Imaging Healthcare Co., Ltd. presented the world's first 5.0T whole-body MRI system, uMRJupiter5T, which offers high-definition imaging for precise diagnosis [1] - Wuhan Heyuan Biotechnology Co., Ltd. introduced the first recombinant human albumin injection derived from rice, which alleviates reliance on imported products and is set to achieve an annual production capacity of 12 million bottles by 2026 [2] - BGI Life Sciences Research Institute announced the global first Stereo-seqV2 technology for spatial transcriptomics, which addresses the challenges of analyzing FFPE samples and has significant implications for precision medicine [3] Technological Innovations - The conference highlighted advancements in brain-machine interface technologies, including a near-infrared brain function imaging system that is the first in China to receive NMPA certification, enabling non-invasive detection of brain activity [4][5] - The high-throughput implantable brain-machine interface system showcased by Wuhan Zhonghua Brain-Machine Fusion Technology Development Co., Ltd. features 65,000 channels for bidirectional functionality, marking a significant leap in system capabilities [5] - The NeuroTuneA1 system developed by Tongji Hospital utilizes focused ultrasound for non-invasive brain-machine treatment, with successful concept validation and animal model testing [6] Industry Trends - China's bioindustry is transitioning from "quantitative accumulation" to "qualitative leap," focusing on core technology breakthroughs, product quality upgrades, and enhancing industry chain resilience [7] - Innovations in synthetic biology and gene editing are driving rapid growth in biomanufacturing, with artificial intelligence playing a crucial role in life science innovation [7] - Future developments in the bioindustry are expected to concentrate on cutting-edge fields such as synthetic biology and brain science to build core competitive advantages [7]

Core Viewpoint - The article discusses the development of a novel spatial multi-omics technology, Spatial-DMT, which enables the simultaneous mapping of DNA methylation and gene expression at near single-cell resolution, enhancing the understanding of tissue biology and its implications in development and disease [2][5][7]. Group 1: Technology Development - The research team from the University of Pennsylvania developed Spatial-DMT, a new technique for spatial profiling of DNA methylome and transcriptome in tissues [2]. - This technology allows for the generation of high-quality DNA-RNA dual-modal tissue maps, revealing how DNA methylation interacts with transcription to define cell identity and drive developmental programs [5][6]. Group 2: Biological Implications - DNA methylation is a key epigenetic mechanism that regulates gene expression and cell states, with abnormal patterns linked to various diseases, including cancer and autoimmune disorders [4]. - The study highlights the dynamic changes in DNA methylation across different cell types and developmental stages, providing insights into the molecular definitions of cell identity during mammalian development and brain function [5][6]. Group 3: Research Applications - The Spatial-DMT technology was applied to mouse embryos and postnatal mouse brains, allowing for the reconstruction of dynamic changes in the epigenome and transcriptome during embryonic development [6]. - The integration of spatial maps from different developmental stages reveals details of transcriptional regulation mediated by sequence, cell type, and region-specific methylation [6][7].

Core Insights - The article discusses the launch of the innovative Stereo-seq V2 technology, which addresses the challenges of analyzing formalin-fixed paraffin-embedded (FFPE) samples, enabling high-resolution real-time monitoring of gene activity in both human cells and invading microorganisms [1][2]. Group 1: Technology Overview - Stereo-seq V2 is described as a "universal key" that unlocks the potential of archived clinical samples, facilitating a shift from merely visualizing cells to understanding the interactions between cells and microorganisms in precision medicine [1][2]. - The technology overcomes significant challenges associated with FFPE samples, such as RNA degradation and molecular cross-linking, through an innovative "repair" process that captures previously overlooked genetic signals [3]. Group 2: Clinical Applications - The introduction of Stereo-seq V2 is seen as a milestone for spatial omics technology, with applications in precision oncology, where it can identify gene copy number variations related to patient prognosis and discover novel gene splice variants that contribute to drug resistance [4]. - In infectious disease contexts, the technology allows for the direct localization of pathogens in tissue samples and assessment of host immune responses, guiding targeted therapies [4]. - The technology also holds promise in antibody drug development by rapidly identifying and locating pathogen-specific neutralizing antibody clones, thus accelerating the drug screening process [4]. Group 3: Previous Achievements - Prior to Stereo-seq V2, the national key laboratory had released the Stereo-cell technology, which achieved breakthroughs in multi-modal integration and in situ dynamic capture, marking a significant advancement in single-cell sequencing capabilities [5].